A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia:

Estibaliz Arce,Rita Balice-Gordon,Sridhar Duvvuri,Melissa Naylor,Zhiyong Xie,Brian T. Harel,Rouba Kozak,David Gray,Nicholas DeMartinis

A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia:

2019

Estibaliz Arce
Rita Balice-Gordon
Sridhar Duvvuri
Melissa Naylor
Zhiyong Xie
Brian T. Harel
Rouba Kozak
David Gray
Nicholas DeMartinis

Background:PF-06412562 is an orally bioavailable, selective dopamine D1/D5 receptor partial agonist with a non-catechol structure under evaluation for treatment of cognitive impairment in schizophr...

Keywords:

Schizophrenia
Pharmacodynamics
Psychology
Anesthesia
Working memory
Dopamine
Partial agonist
Pharmacology
Cognition
Receptor
in patient
cognitive impairment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations